Johnson and Johnson’s Vision Care unit has received FDA approval for its Acuvue Theravision with Ketotifen, a drug-eluting contact lens that could make eyedrops obsolete for contact lens wearers suffering from allergic eye itch. The lens contains 19 mcg of ketotifen, an antihistamine, and has been shown to reduce itchy allergy eyes as quickly as three minutes after lens insertion, lasting up to 12 hours. The product was greenlit for use by the Japanese Ministry of Health almost a year ago. Johnson & Johnson Vision Care Director, Clinical Science, Brian Pall, said the product was popular because it met an unmet need, with 40% of contact lens wearers suffering from itchy-allergy-eyes.

Categorized in: